Payment overview · 2025
General Payments
$273,301.20
157 reported records · 14 companies
Healthcare provider profile · identity verified
Nariman Nezami, MD
Allopathic & Osteopathic Physicians|Radiology|Vascular & Interventional Radiology · BALTIMORE, MD · NPI 1619381506
Verified facts
What the public records show
CMS Open Payments records show Nariman Nezami, MD received $273,301.20 in general payments during 2025 across 157 reported records.
Boston Scientific Corporation accounted for 97.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 34 associated products.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $265,455.31 | 97.1% | 126 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$5,054.26 | 1.9% | 8 | 2025 |
| GUERBET LLC | Unresolved — no canonical attribution shown | $1,479.00 | 0.5% | 4 | 2025 |
| Stryker Corporation | Unresolved — no canonical attribution shown | $464.83 | 0.2% | 4 | 2025 |
| Penumbra, Inc. | Unresolved — no canonical attribution shown | $254.07 | 0.1% | 3 | 2025 |
| Terumo Medical Corporation | Unresolved — no canonical attribution shown | $167.64 | 0.1% | 3 | 2025 |
| Madrigal Pharmaceuticals | Unresolved — no canonical attribution shown | $136.19 | 0.1% | 2 | 2025 |
| Mallinckrodt Hospital Products Inc. | Unresolved — no canonical attribution shown | $79.72 | 0.0% | 1 | 2025 |
| INSTYLLA, INC. | Unresolved — no canonical attribution shown | $54.90 | 0.0% | 1 | 2025 |
| AngioDynamics, Inc. | Unresolved — no canonical attribution shown | $42.88 | 0.0% | 1 | 2025 |
| Bard Peripheral Vascular, Inc. | Unresolved — no canonical attribution shown | $37.25 | 0.0% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $30.23 | 0.0% | 1 | 2025 |
| Okami Medical, Inc. | Unresolved — no canonical attribution shown | $26.88 | 0.0% | 1 | 2025 |
| W. L. Gore & Associates, Inc. | Unresolved — no canonical attribution shown | $18.04 | 0.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $240,875.00 | 44 |
| Travel and Lodging | $16,819.31 | 42 |
| Consulting Fee | $8,006.25 | 3 |
| Food and Beverage | $7,600.64 | 68 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TheraSphere Y90 Glass Microspheres 7.0 GBq (US Commercial) Normalized: therasphere y90 glass microspheres 7 0 gbq us commercial |
Device | Boston Scientific Corporation | $201,304.17 | 58 | 2025 |
Source payment records
|
|||||
| General - Embolics Normalized: general embolics |
Device | Boston Scientific Corporation | $50,104.45 | 32 | 2025 |
Source payment records
|
|||||
| General - Therapies Normalized: general therapies |
Device | Boston Scientific Corporation | $8,012.19 | 10 | 2025 |
Source payment records
|
|||||
| KYPHON EXPRESS II KYPHOPAK TRAY Normalized: kyphon express ii kyphopak tray |
Device | Medtronic, Inc. | $4,650.00 | 1 | 2025 |
Source payment records
|
|||||
| General - IO Ablation Normalized: general io ablation |
Device | Boston Scientific Corporation | $2,800.00 | 1 | 2025 |
Source payment records
|
|||||
| TheraSphere Y90 Glass Microspheres 10 GBq Normalized: therasphere y90 glass microspheres 10 gbq |
Device | Boston Scientific Corporation | $2,192.85 | 13 | 2025 |
Source payment records
|
|||||
| Lipiodol Normalized: lipiodol |
Drug | GUERBET LLC | $1,479.00 | 4 | 2025 |
Source payment records
|
|||||
| OBSIDIO Normalized: obsidio |
Device | Boston Scientific Corporation | $572.09 | 5 | 2025 |
Source payment records
|
|||||
| CT THROMBECTOMY SYSTEM KIT Normalized: ct thrombectomy system kit |
Device | Stryker Corporation | $339.17 | 2 | 2025 |
Source payment records
|
|||||
| FLOWTRIEVER CATHETER, S Normalized: flowtriever catheter s |
Device | Stryker Corporation | $339.17 | 2 | 2025 |
Source payment records
|
|||||
| EMBOLD Fibered Normalized: embold fibered |
Device | Boston Scientific Corporation | $232.66 | 2 | 2025 |
Source payment records
|
|||||
| Indigo System Normalized: indigo system |
Device | Penumbra, Inc. | $168.94 | 2 | 2025 |
Source payment records
|
|||||
| AZUR CX DETACHABLE Normalized: azur cx detachable |
Device | Terumo Medical Corporation | $167.64 | 3 | 2025 |
Source payment records
|
|||||
| REZDIFFRA Normalized: rezdiffra |
Drug | Madrigal Pharmaceuticals | $136.19 | 2 | 2025 |
Source payment records
|
|||||
| SYNCHROMEDII Normalized: synchromedii |
Device | Medtronic, Inc. | $134.93 | 2 | 2025 |
Source payment records
|
|||||
| FLOWTRIEVER Normalized: flowtriever |
Device | Stryker Corporation | $125.66 | 2 | 2025 |
Source payment records
|
|||||
| CONCERTOTM Normalized: concertotm |
Device | Medtronic, Inc. | $116.73 | 1 | 2025 |
Source payment records
|
|||||
| General - Vascular Intervention Normalized: general vascular intervention |
Device | Boston Scientific Corporation | $110.75 | 1 | 2025 |
Source payment records
|
|||||
| INTELLIS ADAPTIVESTIM Normalized: intellis adaptivestim |
Device | Medtronic, Inc. | $98.00 | 3 | 2025 |
Source payment records
|
|||||
| ANGIO-SEAL Normalized: angio seal |
Device | Terumo Medical Corporation | $96.48 | 1 | 2025 |
Source payment records
|
|||||
| TheraSphere Administration Set Normalized: therasphere administration set |
Device | Boston Scientific Corporation | $92.24 | 3 | 2025 |
Source payment records
|
|||||
| RUBY Coil Normalized: ruby coil |
Device | Penumbra, Inc. | $85.13 | 1 | 2025 |
Source payment records
|
|||||
| TERLIVAZ Normalized: terlivaz |
Drug | Mallinckrodt Hospital Products Inc. | $79.72 | 1 | 2025 |
Source payment records
|
|||||
| EMBRACE HYDROGEL EMBOLIC SYSTEM (HES) Normalized: embrace hydrogel embolic system hes |
Device | INSTYLLA, INC. | $54.90 | 1 | 2025 |
Source payment records
|
|||||
| INSTYLLA DELIVERY KIT Normalized: instylla delivery kit |
Device | INSTYLLA, INC. | $54.90 | 1 | 2025 |
Source payment records
|
|||||
| INSTYLLA MICROCATHETER 1.2 Normalized: instylla microcatheter 1 2 |
Device | INSTYLLA, INC. | $54.90 | 1 | 2025 |
Source payment records
|
|||||
| OSTEOCOOL RF ABLATION SYSTEM Normalized: osteocool rf ablation system |
Device | Medtronic, Inc. | $54.60 | 1 | 2025 |
Source payment records
|
|||||
| NAVICROSS Normalized: navicross |
Device | Terumo Medical Corporation | $51.00 | 1 | 2025 |
Source payment records
|
|||||
| ALPHAVAC Normalized: alphavac |
Device | AngioDynamics, Inc. | $42.88 | 1 | 2025 |
Source payment records
|
|||||
| Pristine Normalized: pristine |
Device | Bard Peripheral Vascular, Inc. | $37.25 | 1 | 2025 |
Source payment records
|
|||||
| SpyGlass Discover Normalized: spyglass discover |
Device | Boston Scientific Corporation | $33.91 | 1 | 2025 |
Source payment records
|
|||||
| PERCLOSE PROGLIDE Normalized: perclose proglide |
Device | Abbott Laboratories | $30.23 | 1 | 2025 |
Source payment records
|
|||||
| LOBO Normalized: lobo |
Device | Okami Medical, Inc. | $26.88 | 1 | 2025 |
Source payment records
|
|||||
| GORE VIATORR TIPS Endoprosthesis with Controlled Expansion Normalized: gore viatorr tips endoprosthesis with controlled expansion |
Device | W. L. Gore & Associates, Inc. | $18.04 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $273,301.20 · 157 records | Boston Scientific Corporation | ALPHAVAC, ANGIO-SEAL, AZUR CX DETACHABLE, CONCERTOTM, CT THROMBECTOMY SYSTEM KIT, EMBOLD Fibered, EMBRACE HYDROGEL EMBOLIC SYSTEM (HES), FLOWTRIEVER, FLOWTRIEVER CATHETER, S, GORE VIATORR TIPS Endoprosthesis with Controlled Expansion, General - Embolics, General - IO Ablation, General - Therapies, General - Vascular Intervention, INSTYLLA DELIVERY KIT, INSTYLLA MICROCATHETER 1.2, INTELLIS ADAPTIVESTIM, Indigo System, KYPHON EXPRESS II KYPHOPAK TRAY, LOBO, Lipiodol, NAVICROSS, OBSIDIO, OSTEOCOOL RF ABLATION SYSTEM, PERCLOSE PROGLIDE, Pristine, REZDIFFRA, RUBY Coil, SYNCHROMEDII, SpyGlass Discover, TERLIVAZ, TheraSphere Administration Set, TheraSphere Y90 Glass Microspheres 10 GBq, TheraSphere Y90 Glass Microspheres 7.0 GBq (US Commercial) | — | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error